新辅助治疗对左侧可切除胰腺癌患者的影响:一项国际多中心研究
这项国际多中心回顾性研究纳入2013-2019年18国76中心2282例左侧可切除胰腺癌术后患者,其中290例(13%)接受新辅助治疗。新辅助治疗与总生存延长相关(校正HR 0.69,95%CI 0.58-0.83),校正中位OS为53个月 vs 37个月(P=0.0003),校正5年OS率47% vs 35%(P=0.0001)。肿瘤较大和血清CA19-9较高者中新辅助治疗效果更强。
要点
- 左侧可切除胰腺癌中新辅助治疗与总生存改善相关(校正HR 0.69,95%CI 0.58-0.83)。
- 校正中位OS为新辅助组53个月 vs 直接手术组37个月(P=0.0003)。
- 肿瘤较大(P交互=0.003)和CA19-9较高(P交互=0.005)者中新辅助治疗效果更强。
核心结论
- 左侧可切除胰腺癌患者中新辅助治疗与直接手术相比与总生存改善相关。
- 新辅助治疗的影响随诊断时肿瘤较大和血清CA19-9较高而增强。
- 需要针对左侧可切除胰腺癌患者新辅助治疗的随机对照试验。
研究设计与样本
- 国际多中心回顾性研究,纳入2013-2019年18个国家76个中心连续接受左侧胰腺切除的病理证实可切除胰腺癌患者。
- 共纳入2282例患者,其中290例(13%)接受新辅助治疗。
- 主要终点为自诊断起的总生存,采用时间依赖Cox回归分析校正诊断时混杂因素。
主要发现
- 新辅助治疗与直接手术相比与总生存延长相关(校正HR 0.69,95%CI 0.58-0.83)。
- 校正中位OS为新辅助组53个月 vs 直接手术组37个月(P=0.0003)。
- 校正5年OS率为新辅助组47% vs 直接手术组35%(P=0.0001)。
- 交互分析显示肿瘤较大者中新辅助治疗效果更强(P交互=0.003),血清CA19-9较高者中新辅助治疗效果更强(P交互=0.005)。
- 脾动脉(P交互=0.43)、脾静脉(P交互=0.30)、腹膜后(P交互=0.84)和多脏器(P交互=0.96)受累未增强新辅助治疗效果。
关键数值与推荐
- 新辅助治疗方案最常见为(m)FOLFIRINOX(38%)和吉西他滨-白蛋白结合型紫杉醇(22%)。
- 直接手术后72%患者接受辅助化疗,其中大多数为单药方案(74%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Left-sided pancreatic cancer is associated with worse overall survival (OS) compared with right-sided pancreatic cancer. Although neoadjuvant therapy is currently seen as not effective in patients with resectable pancreatic cancer (RPC), current randomized trials included mostly patients with right-sided RPC. The purpose of this study was to assess the association between neoadjuvant therapy and OS in patients with left-sided RPC compared with upfront surgery. PATIENTS AND METHODS: This was an international multicenter retrospective study including consecutive patients after left-sided pancreatic resection for pathology-proven RPC, either after neoadjuvant therapy or upfront surgery in 76 centers from 18 countries on 4 continents (2013-2019). The primary endpoint was OS from diagnosis. Time-dependent Cox regression analysis was carried out to investigate the association of neoadjuvant therapy with OS, adjusting for confounders at the time of diagnosis. Adjusted OS probabilities were calculated. RESULTS: Overall, 2282 patients after left-sided pancreatic resection for RPC were included of whom 290 patients (13%) received neoadjuvant therapy. The most common neoadjuvant regimens were (m)FOLFIRINOX (38%) and gemcitabine-nab-paclitaxel (22%). After upfront surgery, 72% of patients received adjuvant chemotherapy, mostly a single-agent regimen (74%). Neoadjuvant therapy was associated with prolonged OS compared with upfront surgery (adjusted hazard ratio 0.69, 95% confidence interval 0.58-0.83) with an adjusted median OS of 53 versus 37 months (P = 0.0003) and adjusted 5-year OS rates of 47% versus 35% (P = 0.0001) compared with upfront surgery. Interaction analysis demonstrated a stronger effect of neoadjuvant therapy in patients with a larger tumor (Pinteraction = 0.003) and higher serum carbohydrate antigen 19-9 (CA19-9; Pinteraction = 0.005). In contrast, the effect of neoadjuvant therapy was not enhanced for splenic artery (Pinteraction = 0.43), splenic vein (Pinteraction = 0.30), retroperitoneal (Pinteraction = 0.84), and multivisceral (Pinteraction = 0.96) involvement. CONCLUSIONS: Neoadjuvant therapy in patients with left-sided RPC was associated with improved OS compared with upfront surgery. The impact of neoadjuvant therapy increased with larger tumor size and higher serum CA19-9 at diagnosis. Randomized controlled trials on neoadjuvant therapy specifically in patients with left-sided RPC are needed.
引用
- Rangelova E, Stoop TF, van Ramshorst TME, et al. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Ann Oncol. 2025. PMID: 39814200. doi:10.1016/j.annonc.2024.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。